Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2840
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes? ; volume:19 ; number:1 ; day:7 ; month:1 ; year:2020 ; pages:1-7 ; date:12.2020
Cardiovascular diabetology ; 19, Heft 1 (7.1.2020), 1-7, 12.2020
- Creator
-
Yurista, Salva R.
Silljé, Herman H. W.
Rienstra, Michiel
Boer, Rudolf A. de
Westenbrink, B. Daan
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12933-019-0984-0
- URN
-
urn:nbn:de:101:1-2020041321594973944870
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yurista, Salva R.
- Silljé, Herman H. W.
- Rienstra, Michiel
- Boer, Rudolf A. de
- Westenbrink, B. Daan
- SpringerLink (Online service)
Other Objects (12)
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review
Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)
Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials
Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review
Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)
Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials
Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review
Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)
Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials